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• All endogenous opioid peptides derive from three pre- 
cursor molecules i. e proopiomelanocortin, proenkephalin and 
prodynorphin. The endogenous opioid peptides exert their bio- 
logical effects through opioid receptors. Each endogenous 
opioid peptides exhibits higher binding affinity towards a spe- 
cific type of opioid receptors. Current evidence suggests that 
endogenous opioid peptides play important regulatory roles 
in reproduction. Endogenous opioid peptides are present 
through the hypothalamic-pituitary-gonadal axis. The hypo- 
thalamic opioidergic mechanism represents one of the impor- 
tant central control systems of gonadotropin-releasing hor- 
mone and gonadotropin release. Opioids mediate the sex ste- 
roid effect exerted on gonadotropin-releasing hormone and 
luteinizing hormone secretion and play a crucial role in the 
integration of several neuroendocrine mechanisms. There is 
also evidence that suprahypothalamic mechanism enhances 
endogenous opioid inhibition of gonadotropin-releasing hor- 
mone. The genes of the endogenous opioid peptides are also 
expressed in peripheral reproductive tissues such as the en- 
dometrium and placenta. At least part of the endogenous opioid 
peptides effects may be paracrine or autocrine in nature. The 
possible roles ofopioids in various physiological processes 
of the female reproductive system are also reviewed. 
• Opiate effects on human reproductive function were 
recognized long before the isolation of endogenous peptides 
with opioid activity (1). Since this discovery, research has ex- 
panded greatly and a vast body of literature now documents 
the physiology and pathology of endogenous opioid modula- 
tion of hormonal and other aspects of reproduction. Endog- 
enous opioid peptides (EOF) are present throughout the hypo- 
thalamic-pituitary-gonadal axis as well as in the endometrium 
and placenta. Current evidence suggests that EOF play im- 
portant regulatory roles in reproduction. At least part of EOF 
effects may be local, paracrine or autocrine in nature. It is 
thus possible that local opioids may be part of microregulatory 
loops within each reproductive organ. This review will con- 
centrate on the human data but will refer to animal studies if 
important differences occur or if human data are unavailable. 
OPIOID PEPTIDES AND PRECURSORS 
• Met-enkephalin and leu-enkephalin were the original 
opioids isolated from porcine brain (1). They share the opioid- 
active N-terminal sequence Tyr-Gly-Gly-Phe and differ only 
in their C-active residue methionine and leucine, respectively. 
All opioid peptides share the sequence of either met- or leu- 
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enkephalin at their N-terminal, but possess C-terminal exten- 
sions of variable length, which may confer greater potency 
(2), increased stability against degradation (3) and different 
receptor specificity. Analysis of DNA sequence in recent years 
has allowed the prediction of the amino-acid sequence of three 
precursor molecules (4). 
Proopiomelanocortin (POMC) is a glycoprotein of 31 kD and 
is the precursor for adrenocorticotropic hormone (ACTH), a- 
melanocyte-stimulating hormone (oc-MSH), p-lipotropin and 
also p-endorphin but does not appear to be further processed to 
met-enkephalin. The precursor product relationship was first 
established by radiolabeling studies on AtT-20 cells which de- 
rive from an ACTH-producing tumor or mouse pituitary. The 
final posttranslational products of POMC precursor molecule 
differ between tissues expressing POMC gene. Thus, in ante- 
rior pituitary, the tissue with the highest concentration of 
POMC mRNA and POMC derived peptides, ACTH is the most 
predominant posttranslational product of POMC and plays an es- 
sential role in the hypothalamic-pituitary-adrenal axis. 
Proenkephalin is the major biological source of met-enkepha- 
lin and its extended forms (met-enkephalin-Arg-Phe, met-en- 
kephalin-Arg-Gly-Leu and peptide E) and one source of leu- 
enkephalin. Proenkephalin-derived peptides, in contrast to 
POMC, are all opioids in nature. Each molecule of pro-en- 
kephalin contains seven opioid peptides with the met- or leu- 
enkephalin active core. 
Prodynorphin (proenkephalin B) contains 3 copies of leu-en- 
Table 1. Precursor molecules of opioid peptides 
 
kephalin and its extended forms dynorphin, rimorphin 
(dynorphin B), leumorphin and a-neo-endorphin. Dynorphin 
A, a seventeen amino-acid peptide, was the first posttransla- 
tional product of prodynorphin to be isolated (2,5). Dynorphin 
A and its two smaller fragments have the highest potency of 
all known endogenous opioid peptides in the guinea pig ileum 
bioassay, a characteristic attributed to their high-affinity for 
the K-opioid receptor. In fact it appears that they are the only 
endogenous K-receptor agonists known (6). 
The three opioid precursors are of similar molecular size and 
also contain a number of sequence homologies, suggesting that 
all may have originally derived from an ancestor opioid gene 
(Table 1). 
OPIOID RECEPTORS 
• The EOF exert their biological effects through opioid 
receptors. Each EOF exhibits higher binding affinity towards 
a specific type of opioid receptor. A variety of types of opioid 
receptors have been described. Behavioral studies in dogs sug- 
gested that opioids could be divided into (J,-, K- or o- agonists 
(7). Studies with opioid peptides using bioactivity in periph- 
eral tissue preparations (8), or binding studies of radioactively 
labelled ligands in brain tissue (9) confirmed the existence of 
(a,, 8, K and possibly e- receptors (Table 2). 
The ^-receptor, so named because of its activation by mor- 
phine, mediates analgesia, bradycardia and hypothermia. The 
K-receptor activated by ketocyclazosine, appears to be respon- 
sible for sedation and depression of flexor reflexes, but has no 
involvement in skin twitch reflex or pulse rate. A third class 
of receptors was named o for its activation by SKF 10.047 (N- 
allylnormetazosine). For an effect to be considered consequent 
to opioid receptor activation, the effect must be reversed by 
Table 2. Opioid receptors 
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the classical opioid antagonist naloxone or its more potent 
analogue, naltrexone. The [i- and K-receptor-mediated events 
are readily reversible by naltrexone (7), while physiological 
events effected by o-receptors do not (10). An additional class 
of opioid receptor identified (11) is activated by the enkepha- 
lins and is named 8. 
Other receptors considered to be opioid on the basis of their 
sensitivity to naloxone have been identified in binding stud- 
ies, but a clear functional significance associated with them is 
lacking. Among these receptors are jj.1-receptors mediating 
analgesia and |i2-receptors mediating respiratory depression 
(12). These assumptions are based upon the observation that 
naloxone antagonizes analgesia but not the respiratory depres- 
sion induced by morphine. Unfortunately, there is to date no 
antagonist that can reverse the respiratory depression without 
affecting the analgesia. 
Subtypes of K-receptors have also been proposed (13). There 
may be as many as four subtypes of the K-receptor based upon 
evidence from radioligand binding studies (14). Opioid re- 
ceptors termed e were originally identified as those mediating 
inhibition of electrically evoked twitch in rat vas deferens (15). 
These receptors were believed to be selectively activated by P- 
endorphin. Finally, ?i receptors first described in binding stud- 
ies in rat brain (16) were defined as having high-affinity for 
naloxone, but low affinity for another opioid antagonist, 
diprenorphine. A functional role for this class of opioid recep- 
tors has not yet been proposed. 
LOCALIZATION OF OPIOID PEPTIDES AMD 
RECEPTORS 
• Opioids are localized throughout the central nervous 
system in specific neuron tracts, and separated on the basis of 
their known precursors (17). All opioids are concentrated in 
the hypothalamus, pituitary, periaqueductal grey matter and 
spinal cord. Hypothalamic (3-endorphinergic neurons originate 
largely in the arcuate nucleus from where they project to the 
median eminence as well as other parts of the brain. Enkepha- 
linergic neurons exist in several hypothalamic nuclei while pro- 
dynorphin derived peptides are mostly concentrated in the su- 
praoptic and paraventricular nuclei, although some are also 
present in the arcuate nucleus and posterior hypothalamus (18). 
|i- and K- receptors are present in hypothalamus in roughly 
equal numbers but 8-receptors account for less than 10% of 
opioid binding (9). 
The pituitary contains large amounts of P-endorphin in the 
anterior pituitary corticotroph cells and prodynorphin-derived 
opioids in the posterior pituitary vasopressin neurons (18). 
Met-enkephalin is present in both anterior pituitary soma- 
totrophs (19) and posterior pituitary oxytocin neurons (20). 
Outside the central nervous system opioids are concentrated 
in the adrenal medulla and other parts of the sympathetic ner- 
vous system, and in neurons in the gut. Smaller quantities are 
also described in the testis and pancreas (21). P-endorphin 
and met-enkephalin both circulate in human plasma (22). 
The EOF genes are expressed in most tissues involved in mam- 
malian reproduction. POMC gene is expressed in the hypo- 
thalamus (23), gonads (24), endometrium (25) and placenta 
(26). In all these tissues P-endorphin appears to represent the 
main posttranslational product of POMC. POMC mRNA and 
P-endorphin are present in the granulosa, luteal and intestinal 
cells of female gonads, in the endometrial cells of uterus, and 
in the placental syncytiotrophoblast. The proenkephalin gene 
is expressed in hypothalamus and gonads, and the prodynor- 
phin gene in hypothalamus, anterior pituitary gonadotroph 
cells, male and female gonads, placenta, and endometrium. 
OPIOID PEPTIDES AND CENTRAL REGULATION 
OF THE FEMALE REPRODUCTIVE SYSTEM 
•         Prolactin 
Administration of morphine (27), the enkephalin analogue 
DAMME (FK 33-824) (28), and P-endorphin (29) all cause 
prompt release of prolactin in man. In the rat, P-endorphin is 
a more potent secretagogue than met-enkephalin (30), or 
dynorphin (31), and intraventricular administration of antis- 
era for p-endorphin lowers both basal and stress-induced pro- 
lactin secretion (32), suggesting that p-endorphin is indeed 
the opioid involved. This is compatible with the naloxone sen- 
sitivity of opioid stimulation in man (28) which suggests in- 
volvement of |0,- or e- selective opioids. The opioid effect is 
blocked by the administration of dopamine agonists and po- 
tentiated by dopamine antagonists (33), suggesting that opio- 
ids act by inhibition of dopamine release, the major prolactin 
inhibitory factor from the median eminence. This concept is 
supported by direct experimental evidence in the rat, where 
opioids decrease hypothalamic dopamine turnover (34) and 
release (35). Most studies have failed to find any direct effect 
of opioid peptides on prolactin secretion by isolated pituitary 
cells in vitro. In the rat, naloxone lowers basal, stress-induced 
and suckling-induced prolactin secretion, suggesting an im- 
portant physiological role for opioids on prolactin secretion 
(36). In contrast, most studies have failed to demonstrate an 
effect of naloxone, even at high dosage, on basal or stress- 
induced release of prolactin in normal subjects (37), nor an 
elevated prolactin level in the puerperium (37), or in patients 
with prolactinomas (38). A minority of studies has however 
reported an inhibition of basal or stress-related prolactin re- 
lease (39). High doses of nalo-xone may abolish the exercise- 
induced release of prolactin in highly trained male athletes 
(40). Naloxone infusion (1.6 mg per h) may stimulate pulsa-   
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tile prolactin release in women during the late follicular and 
mid-luteal phases of the menstrual cycle (41) and in women 
under oral contraception (42), but not in early follicular or 
late luteal phase, or in hypogonadal women. This pulsatile 
release of prolactin is synchronous with that of LH, suggest- 
ing that a common mechanism, presumably involving lutein- 
izing hormone-releasing hormone (LHRH), mediates the re- 
lease of both LH and prolactin under these circumstances. In- 
deed, LHRH may stimulate prolactin release, at least in post- 
menopausal women (43), and in vitro evidence suggests that 
this might involve paracrine gonadotroph-lactotroph interac- 
tions (44). In spite of the existence of stimulatory and possibly 
inhibitory opioidergic mechanisms for control of prolactin se- 
cretion, no clear physiological or pathological role has 
emerged. 
         Gonadotropins 
The predominant opioid modulation of gonadotropin secre- 
tion is inhibitory. Chronic opiate addiction has been long rec- 
ognized to cause amenorrhoea and infertility in the female 
(45). Morphine and other opiates decrease serum LH (27). 
Inhibition of follicle-stimulating hormone (FSH) is less con- 
sistently noted, perhaps due to its longer half life in the circu- 
lation. Naloxone acutely increases serum LH and possibly FSH 
in both sexes, suggesting tonic inhibitory opioid control of 
gonadotropin secretion (46). Studies on LH pulsativity indi- 
cate an increase in both frequency and amplitude of LH pulses 
with naloxone in both sexes (46). In females, this effect is 
most marked in the late follicular and particularly mid-luteal 
phase of the menstrual cycle, and opioids may thus mediate 
the slowing of LH pulsativity seen at this time. In normally 
menstruating women, the opioid activity of LH secretion shows 
a fluctuation dependent on the menstrual cycle phase. In the 
early follicular phase, the opioid activity is low, increasing 
proportionately with the ovulatory peak of LH, then remain- 
ing high during luteal phase (47). The high progesterone lev- 
els during luteal phase of menstrual cycle are suggested to 
increase the tone on LH pulsativity (48). Low doses of naloxone 
are required to modulate LH release, suggesting primary in- 
volvement of \i- or e- receptors (48). However, in the imma- 
ture rat, hypothalamic injections of antisera to both (3-endor- 
phin and dynorphin raise LH (49), supposing that more than 
one opioidergic pathway might be involved. Opioid effects 
occur at hypothalamic level and involve modulation of LHRH 
release. Thus opioids have no effect on the LH response to the 
LHRH test (50). LHRH antagonists block naloxone stimula- 
tion in the rat (51), naloxone stimulates the LHRH release 
from human hypothalamus in vitro (52), and morphine de- 
creases hypothalamic LHRH content (53). 
In man, as in the rat, opioidergic regulation mechanisms ap- 
pear to be closely connected to the feedback of gonadal ste- 
roids and LHRH secretion. In postmenopausal women, the en- 
dogenous opioid tone is impaired, as reflected by the lack of 
naloxone effect on plasma LH levels (54). This neuroendo- 
crine response is absent in women with physiological and sur- 
gical menopause (54). Estrogen/progestin therapy affects the 
normal opioidergic tone and restores a concomitant LH re- 
lease after naloxone injection (54). This observation in women 
has been supported by studies in animals. In fact, naloxone 
abolishes the inhibitory effect of sex steroids on LH secretion 
in rats (55). This effect disappears after gonadectomy, and 
naloxone is no longer able to stimulate LH secretion in male 
and female rats. These data suppose that opiodergic regula- 
tion of LH secretion is abolished by the removal of sex ste- 
roids (56). On the other hand, women under hormonal con- - 
traception are also characterized by the absence of the LH re- 
sponse to naloxone (57). Gonadal steroid feedback on LHRH 
may thus be mediated via opioid pathways; however, evidence 
as to whether opioids can inhibit LH secretion in postmeno- 
pausal woman is contradictory. It is therefore possible that the 
presence of gonadal steroids might be necessary for the acti- 
vation of a separate opioid pathway which inhibits LH release. 
Changes in hypothalamic opioid activity have been implicated 
in a number of pathological conditions under which gonadot- 
ropin secretion is reduced. Patients with oligomenorrhoea or 
amenorrhoea secondary to hyperprolactinemia have normal 
mean gonadotropin levels but only infrequent LH pulses of 
large amplitude (58). Infusion of naloxone in such patients 
promptly restores normal LH pulsativity (59) without alterating 
the serum prolactin. This suggests that prolactin inhibits LHRH 
secretion via opioidergic mechanisms. Similar LH responses 
to naloxone have been reported in patients with so-called hy- 
pothalamic amenorrhoea and in the amenorrhoeic athletes (60). 
The correlation is further confirmed by data showing that in- 
duction of ovulation in amenorrhoeic patients restores a nor- 
mal response of LH to naloxone (61). Disturbances of menstrual 
cycle are also correlated with changes in endogenous opioid 
activity. The treatment with naltrexone is effective in some 
patients with hypothalamic amenorrhoea in restoring the ovu- 
latory menstrual cycle (62). Weight loss-related amenor-rhoea 
is also associated with disturbances in LH pulsativity, irrevers- 
ible by naloxone administration (63). In contrast to the rat, the 
majority of patients with anorexia nervosa show no gonadot- 
ropin response to naloxone (63), and those patients who do re- 
spond may have another preexisting cause for amenorrhoea 
(64). Similarly, patients with Kallman's syndrome and idio- 
pathic hypopituitarism show no response to naloxone (65). In 
polycystic ovary syndrome, the absence of response of LH to 
naloxone has been reported. In these women the hyperandro- 
genic state leads to an amenorrhoeic state which, in some pa- 
tients, is opioid-dependent (66). In comparison, menstruating 
hyperandrogenic patients have a normal response to naloxone 
during luteal phase of menstrual cycle, even in the presence of   
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oligomenorrhoea (67). Finally, it has been suggested that opio- 
ids might play a role in the premenstrual syndrome (68). 
Oxytocin  
In the rat, opioids appear to inhibit oxytocin release in vivo in 
response to suckling and other stimuli (69), and naloxone po- 
tentiates oxytocin secretion from electrically stimulated rat neu- 
rohypophysis in vitro (70). Met-enkephalin is colocalized with 
oxytocin in the magnocellular neurons projecting to the pos- 
terior pituitary (20) and may thus be coreleased into plasma. 
Opioid inhibition of oxytocin release may therefore represent 
an ultra-short loop feedback at pituitary level (70). Studies in 
the rat have suggested that central inhibitory opioid control of 
oxytocin secretion may regulate "spacing" of successive births 
during parturition and mediate the interruption of parturition 
by environmental stressors (71). 
•         Opioids and sexual maturation 
Low plasma sex hormone levels are typical in normal prepuber- 
tal children in both sexes. A lack of LH release to naloxone 
administration before sexual maturation has been observed 
(72). With the advanced stages of pubertal development, the 
LH response to naloxone appears in conjuction with the start- 
ing of plasma LH pulsativity. The initial increase of LH after 
naloxone administration is observed in children at the Tanner 
pubertal stage of 4-5 (73). These observations in humans were 
confirmed by several studies in rats. The hypothalamus is ready 
to produce GnRH before the onset of puberty but pulses of 
GnRH may be observed in association with the maturation of 
the opioid system. A segmentation of POMC mRNA in the 
arcuate nucleus is shown at the onset of puberty in rats (74). 
In immature rats, both antagonists and agonists of opioid re- 
ceptors do not change plasma LH or GnRH-stimulated gona- 
dotropin release from anterior pituitary. Moreover, an age- 
related reduction of LH-sensitivity to opioids and lack of de- 
crease of LH secretion after opiate peptide administration has 
been described in prepubertal rats. Based on these data some 
authors propose to identify the EOF as "gonadostats" (75). 
•         Opioids and hypogonadic states 
A failure of naloxone administration in increasing plasma LH 
levels has been observed in various primary as well as second- 
ary hypogonadal states. Klinefelter's and Turner's syndromes 
are examples of primary hypogonadism (76). In patients with 
these syndromes, the naloxone administration is ineffective in 
stimulating LH release, even after prolonged sex steroid therapy 
(76). Children with idiopathic precocious puberty do not show 
any change of plasma LH levels following treatment with 
naloxone or naltrexone. Moreover, a failure of the opioidergic 
tone is confirmed in patients with Kallman' s syndrome, in view 
of the primary defect of hypothalamic GnRH production (63). 
•         Central opioid-sex steroid interactions 
A close relationship between the central endogenous opioid 
system and sex steroids is confirmed by several studies con- 
ducted both in vivo and in vitro. Using autoradiography and 
immunocytochemistry, it has been found that arcuate nucleus 
of the hypothalamus contains estradiol-concentrating neurons 
as well as p-endorphin-like immunoreactivity. A subpopula- 
tion of the arcuate nucleus P-endorphin neurons is receptive 
to the estradiol (77). Centrally microinfused P-endorphin modi- 
fies mammalian "sexual behaviour" and abolishes the estro- 
gen-dependent lordosis in castrated and estrogen primed rats 
(78). It has also been reported that estrogen reduces hypotha- 
lamic POMC mRNA (79). A small population of hypotha- 
lamic P-endorphin producing neurons contains progesterone. 
This finding may indicate that the stimulatory effect of proges- 
terone on GnRH and LH secretion is mediated at least in part 
by the endogenous opioid system. The reduction of opioid bind- 
ing sites in mediobasal hypothalamus and preoptic area is 
linked to progesterone-induced LH surge (80). An increase of 
hypothalamic P-endorphin content has also been observed fol- 
lowing a chronic treatment with various progestins in 
ovariectomized rats (81). 
Taken together these studies indicate that the endogenous 
opioid system is involved at least in part in the central control 
of GnRH and gonadotropin release. Opioids mediate the sex 
steroid effect exerted on GnRH and LH secretion and play a 
crucial role in several neuroendocrine mechanisms involved 
in reproduction.  
OPIOID PEPTIDES AND PERIPHERAL 
REGULATION OF THE FEMALE REPRODUCTIVE 
SYSTEM 
•        Ovaries 
Immunoreactive P-endorphin is present in the ovaries of many 
species including rodent (82) and human (83). Most of this 
material has the molecular weight of authentic p-endorphin 
while a significant percentage exhibits higher molecular weight 
(84). It has been reported that the proenkephalin mRNA is 
present in rat ovaries and that its concentration changes mark- 
edly during the estrus cycle (85). Immunoreactive dynorphin 
and prodynorphin mRNA are also detectable in rat ovaries 
(86). Immunocytochemical and in situ hybridization data show 
that the granulosa and luteal cells appear to be the predomi- 
nant source of ovarian POMC-derived opioids. The evalua- 
tion of p-endorphin in follicular fluid shows a preovulatory 
increase of p-endorphin levels, despite constant ACTH and 
p-lipotropin concentrations throughout the different phases 
of menstrual cycle (87). This pattern appears again in supero-   
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vulated follicles, supposing the existence of a relationship be- 
tween follicle maturation and POMC expression. Ovarian P- 
endorphin (88) and POMC mRNA rise sharply on the evening 
of proestrus, suggesting that its synthesis is regulated by go- 
nadotropins and gonadal steroids (89) (Table 3). 
The physiological significance of opioids in growing follicle 
and in corpus luteum is still unknown (82). Recent data indi- 
cate that the immature follicle contains lower P-endorphin 
amounts than the preovulatory, fully mature follicle exposed 
to gonadotropin stimulation. This confirms that P-endorphin 
is the end product of POMC in ovulatory dominant follicle. 
The increase of follicular p-endorphin in preovulatory follicle 
could be related to the isolated (3-endorphin peak described in 
peripheral circulation around the ovulatory period (90). The 
absence of a concomitant (3-lipotropin rise has been inter- 
preted as a phenomenon independent of the anterior pituitary 
secretion (90). The finding that plasma P-endorphin peak oc- 
curs only in the ovulatory cycles (87) led to the hypothesis 
that "ovarian endorphin" could contribute to peripheral P-en- 
dorphin levels in certain circumstances, such as the ovula- 
tion.  
A pattern opposite to that described for p-endorphin exists as 
far as ACTH and its products are concerned. This indicates 
that not only the synthesis of POMC mRNA (82) but also the 
posttranslational processing of POMC are a function of the 
ovarian cycle. In this respect, the changes of y-endorphin in 
follicular fluid are worth mentioning. Since y-endorphin lev- 
els are higher in immature follicles than in superovulated ones 
and luteinized unruptured follicles, it could be hypothesized 
that maturational processes of granulosa cells inhibit the con- 
version of P-endorphin into Y-endorphin. The peptide pattern 
in luteinized unruptured follicles is superimposable to that of 
superovulated follicles with the only exception of P-endorphin 
levels which remain lower. Since the increased concentration 
of P-endorphin is a typical sign of follicle maturation, it is 
possible to speculate that this opioid is involved in the ovula- 
tion process. Different substances, including progesterone and 
Table 3. Expression of endogenous opioids in female repro- 
ductive organs 
prostaglandins, regulate locally the follicle rupture through a 
coordinate action on both plasmin production and muscularis 
mucosae contraction (91). Follicular P-endorphin could there- 
fore interfere with this mechanism in view of the possible pres- 
ence of opiate receptors in ovarian cells (92). 
In conclusion, all these data demonstrate that the POMC pro- 
cessing in the follicle changes as a function of ovarian endo- 
crine activity. Moreover, the reduced P-endorphin levels in 
the luteinized unruptured follicles support the hypothesis that 
these peptides could be involved in mechanisms leading to 
follicle collapse (83). 
•         Uterus  
All three opioid peptide precursors are synthesized in mam- 
malian uterus. Current experimental evidence suggests that 
the POMC gene is expressed in human endometrium and the 
size of its transcript is similar to that present in pituitary (25). 
The prodynorphin gene is also expressed in human endome- 
trial cells, giving a transcript similar in size to that present in 
rat anterior pituitary (93). In the rat uterus, the prodynorphin 
gene is also expressed, but the size of its transcript (2.2 Kb) is 
200 bases smaller to that reported in rat hypothalamus (86). 
The proenkephalin mRNA has also been detected in the 
macaque uterus with higher levels observed during the prolif- 
erative phase of the menstrual cycle (94), suggesting a regula- 
tory role of estrogens. On the other hand, in the rodent uterus, 
progesterone has been shown to increase both met-enkephalin 
secretion and proenkephalin A mRNA levels, while the higher 
levels of proenkephalin expression occur during metestrus and 
diestrus of normally cycling rats (95). These data propose 
highly divergent regulator}' mechanisms for proenkephalin ex- 
pression between primate and rodent uteri. It appears also that 
progesterone stimulates endometrial P-endorphin since the 
latter is only detectable in the proliferative human endometrium 
(96) and increases the secretion of P-endorphin in the uterus 
of ovariectomized gilts (97). In Ishikawa human endometrial 
cells, which has been shown to be a good in vitro model for 
the study of the effects of steroid hormones on human epithe- 
lial endometrium, the apparent molecular weight of the se- 
creted P-endorphin is that of authentic p-endorphin (25), while 
the bulk of secreted dynorphin had an apparent molecular 
weight of 8 kD (93). Estrogen and glucocorticoids decrease |3- 
endorphin secretion from Ishikawa cells (25), while both 
progesterone and dihydrotestosterone do not significantly af- j 
feet it (25). The antiprogestin-antiglucocorticoid RU-486 acts '• 
as an agonist, diminishing P-endorphin secretion possibly via 
glucocorticoid receptors (25). On the other hand, the secre- 
tion of endometrial dynorphins is not affected by any of these 
steroids, while LHRH induces a significant increase of 
dynorphin secretion without affecting that of P-endorphin (93). ; 
These data suggest that the regulation of endometrial opioids \ 
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is type-specific. Thus it is possible that each type of endome- 
trial opioid participates in different local homeostatic loops 
and exerts dinstict paracrine effects. 
The role that the endometrial opioids plays within the uterine 
cavity is still largely unknown. In general, it is postulated that 
opioids of peripheral tissue have local, paracrine or autocrine 
effects. Endometrial p-endorphin may also act locally, since it 
has been shown that K-opioid receptors are present in human 
endometrial cells (98) and p-endorphin increases the concen- 
tration of estrogen receptors in uterine epithelial cells, thus af- 
fecting the sensitivity of endometrium to estrogens (99). In ad- 
dition, endometrial opioids may exert a number of other func- 
tions, such as relaxation of smooth muscle (100). Smooth 
muscle bundles contained in the supportive ligaments as well 
as in the circular muscle system of the uterus undergo contrac- 
tions during the preovulatory peak of estrogens. This coordi- 
nation of muscular contractions plays an important role in 
properly orienting the ovary with the infundibulum of the fal- 
lopian tube at the time of ovulation, and any pathological con- 
dition interfering with this coordination may be a cause of 
dysmenorrhea. The preovulatory peak of estrogens by decreas- 
ing endometrial p-endorphin release could potentially facili- 
tate the uterine contractions necessary for efficient movement 
of the ovum into the tube or the transport of the sperm through 
the uterine cavity. 
Numerous findings propose an immunological role of opioid 
peptides (101). Recent data show that the corticotropin-releas- 
ing hormone (CRH) gene is expressed in normal and tumoral 
epithelial cells of human endometrium (26). The coexpression 
in endometrial epithelial cells of both CRH and POMC sug- 
gests that endometrial CRH may have an autocrine or paracrine 
effect on endometrial POMC-derived peptide secretion, as in 
placenta and testes (26). The involvement of CRH in the in- 
flammatory process has been recently established. CRH has 
been detected in inflammatory sites, whereas immunoneutrali- 
zation of CRH attenuates the inflammatory response (102). It 
is possible that endometrial CRH participates in the regula- 
tion of immunological events taking place within the uterine 
cavity, specifically in egg nidation and implantation. It is 
known that (/) the human blastocyst secretes prostaglandin E, 
(PGE,) (103), 00 PGE, promotes the attachment and implan- 
tation of the blastocyst (103), (/"//) PGE, is a major inducer of 
CRH expression in the placenta (104), and (iv) POMC-de- 
rived P-endorphin possesses immunosupressive properties 
(101). From these data the following scenario during egg im- 
plantation could take place: the blastocyst secretes PGE, at 
the site of nidation, which among other things, stimulates the 
production of CRH from the endometrium; subsequently, CRH 
participates in local events culminating in the attachment of 
the egg; at the same time, endometrial CRH may also sup- 
press inflammatory response by augmenting the production of 
local, endometrial P-endorphin, which will produce a con- 
fined immunosupression at the site of nidation, inhibiting the 
rejection of the semixenograft. Thus, another potential site of 
action of endometrial P-endorphin could be its participation, 
along with glucocorticoids, interleukins (26) and CRH, in en- 
dometrial immunological events associated with egg im- 
plantation. Here, it is worth mentioning that oc-MSH exerts 
an antiinflammatory effect (105) and GnRH and LH nega- 
tively influence B lymphopoiesis (106). 
•         Placenta         
The human placenta is rich in a variety of opioids including 
P-endorphin (102), met- and leu-enkephalin and dynorphin 
(103) (see Table 3). Synthesis of P-endorphin, p-lipotropin 
and ACTH, as well as a number of higher molecular weight 
precursors has been demonstrated by pulse-chase experiments 
in cultured placental trophoblasts (104). The posttranslational 
processing of placental POMC is similar to that in hypothala- 
mus and gonadal tissues since most of the POMC-derived pep- 
tides present have the physicochemical characteristics of a- 
MSH and P-endorphin (103). However, as with other repro- 
ductive tissues, placental POMC mRNA is by about 300 nucle- 
otides shorter than its pituitary counterpart (107). Prodynor- 
phin-derived opioids have been also detected in human pla- 
centa (103). Immunohistochemically, placental POMC-derived 
peptides are localized in the villous syncytiotrophoblast, where 
most of placental pituitarylike hormones are synthesized (108). 
It has been found that POMC-derived peptides are being se- 
creted from perfused human placental slices in vitro and from 
placental trophoblasts in culture (104), and the secretion rate 
of P-endorphin is higher than that of ACTH (26). 
A number of substances affect the secretion of placental POMC- 
derived peptides. CRH-binding sites are present in human pla- 
centa (109) and CRH stimulates the secretion of all placental 
POMC-derived peptides (26). Glucocorticoids suppress de novo 
synthesis of POMC in anterior pituitary corticotrophs (110), 
but they appear not to affect the secretion of POMC-derived 
peptides from perfused placental slices in vitro. The oxytocin 
gene is expressed in reproductive tract tissues and an oxyto- 
cin-like substance has been identified in human placenta. The 
secretion of all placental POMC-derived peptides is stimu- 
lated by oxytocin in a dose-depended manner (26). Prostag- 
landins increase plasma and amniotic fluid levels of p-endor- 
phin in pregnant women undergoing prostaglandin-induced 
therapeutic abortion at the second trimester of pregnancy (111). 
In addition, prostaglandins stimulate the secretion of placen- 
tal POMC-derived peptides (104). Their effect on placental 
POMC may be mediated by CRH since the addition of a CRH 
antagonist causes a partial block of the stimulatory effect of 
prostaglandins on placental POMC (104). K-opioid binding 
sites, for which prodynorphin-derived opioids are the main   
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endogenous agonist, are also present (112), suggesting that 
placental dynorphins may have a local effect.  
The physiological significance of placental POMC-derived pep- 
tides remains unknown. They could act either locally or sys- 
tematically. There are local effects of placental ACTH which 
involve stimulation of the release of intrauterine prostaglan- 
dins and of the secretion of progesterone and estrogens by 
placenta in vitro (113). (3-endorphin has preferential affinity 
proposed as the prototype ligand for the e-opioid receptors 
identified in the rat vas deferens (114). It appears that opioids 
stimulate the secretion of hCG from first trimester human tro- 
phoblasts in vitro and reduce placental acetylcholine release 
into the fetal vessels (115). In addition, an inhibitory action of 
opioid peptides on placental GnRH release, similar to that 
found in hypothalamic GnRH neurons, has also been observed 
(115). Recent evidence suggests that placental steroid hor- 
mones and endogenous opioid peptides may also modulate the 
release of GnRH (115). Collectively, these findings suggest 
that the locally produced steroids and opioid peptides partici- 
pate in the overall regulation of hCG secretion by the 
syncytiotrophoblast. The presence of receptors for estrogen, 
progesterone and opioid peptides in human placenta (116) sup- 
ports this hypothesis. 
As for the distal effects of placental POMC-derived peptides, 
it has been suggested that a significant percentage of maternal 
plasma ACTH and [3-endorphin originate in placenta. Thus, 
placental ACTH may participate in the regulation of the ma- 
ternal hypothalamus-pituitary-adrenal axis, while placental P- 
endorphin may play a role in the inhibition of oxytocin, 
vassopressin and gonadotropin secretion, the promotion of 
prolactin release, and in the modulation of pain threshold dur- 
ing pregnancy and parturition (117).  
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